Carregant...
Current State of Type 1 Diabetes Immunotherapy: Incremental Advances, Huge Leaps, or More of the Same?
Thus far, none of the preclinically successful and promising immunomodulatory agents for type 1 diabetes mellitus (T1DM) has conferred stable, long-term insulin independence to diabetic patients. The majority of these immunomodulators are humanised antibodies that target immune cells or cytokines. T...
Guardat en:
Autors principals: | , , |
---|---|
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
Hindawi Publishing Corporation
2011
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3139873/ https://ncbi.nlm.nih.gov/pubmed/21785616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/432016 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|